{"entity":{"id":"kymathera","kind":"company","name":"KymaThera","aka":[],"tldr":"KymaThera is developing K-1728, a pill that blocks the faulty forms of the PI3K-alpha enzyme found in many hormone receptor-positive breast cancers while largely sparing the normal enzyme. It expected to start its first human trial in late 2026.","summary":"KymaThera, based in San Diego, develops small-molecule precision therapeutics. Its lead, K-1728, is an oral pan-mutant-selective PI3Kα inhibitor designed to inhibit both kinase-domain and helical-domain PIK3CA mutations while largely sparing wild-type PI3Kα. It is being developed for HR-positive, HER2-negative breast cancer, alone and in combination, and as monotherapy for PI3Kα-driven vascular malformations. In October 2026 the company closed an USD 80 million Series B led by Alta Partners with Venrock, Foresite Capital and J. Wood Capital, bringing total capital raised to more than USD 100 million; it expected to dose the first patient in a phase 1 study in the fourth quarter of 2026. Rob Kania is chief executive.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://kymathera.com/"},{"label":"Series B release, October 2026","url":"https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["pi3k-akt-mtor-inhibitors","kinase-inhibitors"],"targets":["pik3ca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and headquarters address not stated on the company website; San Diego is the dateline of the Series B release. The 2024 Series A is the earliest financing found; whether an earlier seed round existed was not established. No human data had been reported at the time of writing."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://kymathera.com/","stage":"startup","investors":["venrock","foresite-capital"],"funding":[{"round":"Series A","year":2024,"source":"https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html","note":"Co-led by Foresite Capital and Venrock; amount not disclosed (reported in the Series B release)"},{"round":"Series B","year":2026,"amountUsd":80000000,"source":"https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html","note":"Led by Alta Partners with Venrock, Foresite Capital and J. Wood Capital"}]},"route":"/companies/kymathera/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"company":[{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/"},{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/"}]}}